Cargando…

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia

The emergence of the Omicron variant has generated concerns about the efficacy of COVID-19 vaccines. We evaluated the serum neutralizing activity of antibodies against the Omicron (lineage BA.1.1) by plaque reduction neutralizing test, as well as its correlation with age and gender, in a Colombian c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zapata-Cardona, María I., Flórez-Álvarez, Lizdany, Lopera, Tulio J., Chvatal-Medina, Mateo, Zapata-Builes, Wildeman, Diaz, Francisco J., Aguilar-Jimenez, Wbeimar, Taborda, Natalia, Hernandez, Juan C., Rugeles, Maria T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811190/ https://www.ncbi.nlm.nih.gov/pubmed/36618393 http://dx.doi.org/10.3389/fimmu.2022.1102384

Ejemplares similares

Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
por: Lopera, Tulio J., et al.
Publicado: (2022)

NK cells from Men Who Have Sex with Men at high risk for HIV-1 infection exhibit higher effector capacity
por: Rincón, Daniel S., et al.
Publicado: (2023)

In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach
por: Zapata-Cardona, Maria I., et al.
Publicado: (2023)

Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms
por: Marín-Palma, Damariz, et al.
Publicado: (2021)

The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro
por: Yepes-Perez, Andres F., et al.
Publicado: (2021)

Atorvastatin Effectively Inhibits Ancestral and Two Emerging Variants of SARS-CoV-2 in vitro
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Comparison among plaque assay, tissue culture infectious dose (TCID(50)) and real-time RT-PCR for SARS-CoV-2 variants quantification
por: Zapata-Cardona, Maria Isabel, et al.
Publicado: (2022)

PM10 promotes an inflammatory cytokine response that may impact SARS-CoV-2 replication in vitro
por: Marín-Palma, Damariz, et al.
Publicado: (2023)

High Transcript Levels of Vitamin D Receptor Are Correlated with Higher mRNA Expression of Human Beta Defensins and IL-10 in Mucosa of HIV-1-Exposed Seronegative Individuals
por: Aguilar-Jiménez, Wbeimar, et al.
Publicado: (2013)

A specific structure and high richness characterize intestinal microbiota of HIV-exposed seronegative individuals
por: Lopera, Tulio J., et al.
Publicado: (2021)

Genetic and Immunological Factors Involved in Natural Resistance to HIV-1 Infection
por: Taborda-Vanegas, Natalia, et al.
Publicado: (2011)

High Expression of Antiviral Proteins in Mucosa from Individuals Exhibiting Resistance to Human Immunodeficiency Virus
por: Gonzalez, Sandra Milena, et al.
Publicado: (2015)

Immune characterization of a Colombian family cluster with SARS-CoV-2 infection
por: Aguilar-Jiménez, Wbeimar, et al.
Publicado: (2021)

NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies
por: Flórez-Álvarez, Lizdany, et al.
Publicado: (2018)

Randomized double-blind clinical study in patients with COVID-19 to evaluate the safety and efficacy of a phytomedicine (P2Et)
por: Urueña, Claudia, et al.
Publicado: (2022)

Plasma metabolomics by nuclear magnetic resonance reveals biomarkers and metabolic pathways associated with the control of HIV-1 infection/progression
por: Gómez-Archila, León Gabriel, et al.
Publicado: (2023)

Vitamin D treatment of peripheral blood mononuclear cells modulated immune activation and reduced susceptibility to HIV-1 infection of CD4(+) T lymphocytes
por: Gonzalez, Sandra M., et al.
Publicado: (2019)

Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia
por: Díaz, Francisco J., et al.
Publicado: (2020)

The Usefulness of Antigen Testing in Predicting Contagiousness in COVID-19
por: Lopera, Tulio J., et al.
Publicado: (2022)

Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia
por: Álvarez-Díaz, Diego A., et al.
Publicado: (2022)

SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population
por: Patarroyo, Manuel A., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

NK Cell Activity and CD57(+)/NKG2C(high) Phenotype Are Increased in Men Who Have Sex With Men at High Risk for HIV
por: Flórez-Álvarez, Lizdany, et al.
Publicado: (2020)

Seronegative MSM at high risk of HIV-1 acquisition show an immune quiescent profile with a normal immune response against common antigens
por: Ossa-Giraldo, Ana C., et al.
Publicado: (2022)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Development of an optimized method for processing peripheral blood mononuclear cells for (1)H-nuclear magnetic resonance-based metabolomic profiling
por: Gómez-Archila, León Gabriel, et al.
Publicado: (2021)

1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
por: Debie, Y., et al.
Publicado: (2022)

Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults
por: Um, Jihye, et al.
Publicado: (2022)

Dynamics of humoral immune response in SARS-CoV-2 infected individuals with different clinical stages
por: Mendez-Cortina, Yorjagis, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_um9gugvn3ajnf47rcud99kib14